About TriSalus Life Sciences
TriSalus Life Sciences is a company based in Westminster (United States) founded in 2009. TriSalus Life Sciences has raised $83.37 million across 12 funding rounds from investors including MCG Capital, Nantahala Capital Management and Broadfin Capital. The company has 110 employees as of December 31, 2024. TriSalus Life Sciences offers products and services including Drug Delivery Technology, nelitolimod, and TriNav Infusion System. TriSalus Life Sciences operates in a competitive market with competitors including Insulet, Lyra Therapeutics, Credence MedSystems, Foresee Pharmaceuticals and Cellectar Biosciences, among others.
- Headquarter Westminster, United States
- Employees 110 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Trisalus Life Sciences, Inc.
-
Annual Revenue
$29.43 M (USD)58.99as on Dec 31, 2024
-
Net Profit
-$30.05 M (USD)49.39as on Dec 31, 2024
-
EBITDA
-$35.16 M (USD)33.15as on Dec 31, 2024
-
Total Equity Funding
$83.37 M (USD)
in 12 rounds
-
Latest Funding Round
$22 M (USD), Post-IPO
Apr 30, 2025
-
Investors
MCG Capital
& 8 more
-
Employee Count
110
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of TriSalus Life Sciences
TriSalus Life Sciences is a publicly listed company on the NASDAQ with ticker symbol TLSI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of TriSalus Life Sciences
TriSalus Life Sciences offers a comprehensive portfolio of products and services, including Drug Delivery Technology, nelitolimod, and TriNav Infusion System.
Platform for enhancing drug delivery to tumors.
Candidate therapy for liver and pancreatic tumor treatment.
System for pressure-enabled drug administration in tumors.
People of TriSalus Life Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of TriSalus Life Sciences
TriSalus Life Sciences has successfully raised a total of $83.37M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $22 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TriSalus Life Sciences
TriSalus Life Sciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include MCG Capital, Nantahala Capital Management and Broadfin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment opportunities in healthcare are managed by Broadfin Capital.
|
Locked | Locked | Locked | |
|
A venture capital firm focused on early-stage biotech investments.
|
Locked | Locked | Locked | |
|
Healthcare investments are made by Tullis Health Investors.
|
Locked | Locked | Locked |
Investor details for TriSalus Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TriSalus Life Sciences
Investment portfolio details for TriSalus Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TriSalus Life Sciences
Detailed financials for TriSalus Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trisalus Life Sciences Comparisons
Peer comparison for TriSalus Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TriSalus Life Sciences
TriSalus Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, Credence MedSystems, Foresee Pharmaceuticals and Cellectar Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for ENT diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of smart devices for drug delivery
|
|
| Locked | Locked | Locked |
Injectables and NCEs for cancer and chronic diseases are developed.
|
|
| Locked | Locked | Locked |
Phospholipid drug conjugates for cancer treatment are developed.
|
Detailed competitors of TriSalus Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trisalus Life Sciences
Complete news archive for TriSalus Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TriSalus Life Sciences
TriSalus Life Sciences was founded in 2009 and raised its 1st funding round 2 years after it was founded.
TriSalus Life Sciences is headquartered in Westminster, United States.
TriSalus Life Sciences is a funded company, having raised a total of $83.37M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at TriSalus Life Sciences is 110.
Annual revenue of TriSalus Life Sciences is $29.43M as on Dec 31, 2024.
TriSalus Life Sciences is involved in developing drug delivery devices to treat cancers. They have developed a technology platform, Pressure-Enabled Drug Delivery (PEDD), which is designed to improve the distribution and penetration of therapy in solid tumors.
TriSalus Life Sciences's top competitors include Insulet, Lyra Therapeutics and Mercator MedSystems.
TriSalus Life Sciences offers Drug Delivery Technology, nelitolimod, and TriNav Infusion System.
Yes, TriSalus Life Sciences is publicly traded on NASDAQ under the ticker symbol TLSI.
TriSalus Life Sciences has 9 investors. Key investors include MCG Capital, Nantahala Capital Management, Broadfin Capital, ORI Capital, and Tullis Health Investors.
The ticker symbol of TriSalus Life Sciences is TLSI on NASDAQ.